Candel Therapeutics, Inc.

File BLA for aglatimagene besadenovec in prostate cancer

Deadline not yet reached (65 days left)

Announced: 9 Sep 2026
Due: 31 Dec 2026

Deadline
Met
Late
Not met
Today

What the company said

“2026 BLA filing Updated New OS data, biomarker data, recurrent HGG prostate cancer Phase 1b”

SourceCandel Therapeutics, Inc. Form 8-K press release, 2026-09-09
Archived copyWayback Machine snapshot
FilingSEC filing index
Deadline as stated2026
Deadline used31 Dec 2026, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2026-CADL-000585
Cite as https://keptindex.org/c/KI-C-2026-CADL-000585/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory submission
Indicative materiality: High rules
Action: File

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedRecorded from the company's filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Candel Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-CADL-000585 · Corrections policy